Smeets Tom SRL
4.2 FTESmeets Tom reported total assets of €1.01m at the end of the 2025 financial year (annual accounts filed with the NBB on 27 Aug 2026), with 4.2 full-time equivalents.
The score of Smeets Tom shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -7 % Total assets -10 % Headcount (avg FTE) -7 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Smeets Tom's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 27 Aug 2026
- Year ended 31 Dec 2024filed on 29 Sep 2025
- Year ended 31 Dec 2023filed on 19 Aug 2024
- Year ended 31 Dec 2022filed on 31 Aug 2023
- Year ended 31 Dec 2021filed on 30 Aug 2022
Smeets Tom's financial analysis
- Solvency2.4%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Smeets Tom
Smeets Tom's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0419.717.317
- VAT number
- BE0419717317
- Peppol
- Registered · 0208:0419717317 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 01 Jul 1979
- Registered office
- 2547 Lint
- Size
- Micro · 4.2 FTE
- Latest accounts
- 2025 · filed on 27 Aug 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Smeets Tom (SRL) has been based in Lint since 1979, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 134,153 € and equity of 24,512 €; its revenue is not published. With 4.2 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 2.4%, below the median of its sector (44.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Smeets Tom
Companies in the same business, of comparable size and area, outside its group.
- Pharmacie Cathedrale Retail sale of pharmaceutical products Liège · balance sheet €1.01m
- Apotheek Ilse Caudron Retail sale of pharmaceutical products Aalst · balance sheet €1.01m
- Pharm TG Retail sale of pharmaceutical products Sambreville · balance sheet €1.01m
- Wezefarma Retail sale of pharmaceutical products Rotselaar · balance sheet €1.01m
- Distephar Retail sale of pharmaceutical products Zedelgem · balance sheet €1.01m
- Valophar Retail sale of pharmaceutical products Gembloux · balance sheet €1.02m
- Digitale Pharma Retail sale of pharmaceutical products Bernissart · balance sheet €1.00m
- Pharmapoint Retail sale of pharmaceutical products Maasmechelen · balance sheet €1.02m
Frequently asked questions about Smeets Tom
What is the revenue of Smeets Tom?
Smeets Tom files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Smeets Tom?
In Belgium, the VAT number is the company number prefixed with BE: BE0419717317 for Smeets Tom, if the company is VAT-registered. Its company number (CBE) is 0419.717.317.
Where is the registered office of Smeets Tom?
According to the CBE register, the registered office of Smeets Tom is in 2547 Lint.
What is the equity of Smeets Tom?
At the close of the 2025 financial year, the equity of Smeets Tom amounts to 24,512 €, a solvency of 2.4% of total assets.
How many people work at Smeets Tom?
4.2 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Smeets Tom?
The register lists 1 active mandates at Smeets Tom. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Smeets Tom
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →